Drug Trial Radar · NCT04729907
A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)
Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
115
Actual
Start
Apr 19, 2021
Primary completion
Jul 30, 2026
Study completion Jul 30, 2026
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Jan 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, researchers will learn more about the use of nusinersen (BIIB058) in participants with spinal muscular atrophy (SMA). This study is an extension study and will enroll only those participants who have completed treatment in the parent study, 232SM203. The main goal of the study is to learn about the long-term safety of nusinersen. The main questions researchers want to answer are: * How many participants have adverse events and serious adverse events during the study? * How do the results of electrocardiograms (ECGs), vital signs, and laboratory tests including blood and urine tests change after treatment? * How many participants have a low platelet count after treatment? * How many participants had a change in the time it took for their heart to recharge between beats after treatment? * How does each participant's height and other measures of growth change after treatment? * How much do the results of neurological exams that check movement, reflexes, and brain function change after treatment? Researchers will also learn about the effect of nusinersen on mobility using various tests. They will study body movements, reflexes, balance, and coordination. They will also record if participants need help with breathing. The 232SM302 study will be done as follows: * Participants will be screened to check if they can join the study. * Participants will receive their 1st dose of nusinersen in this study about 4 months after their final dose in the parent study. * Each participant will receive nusinersen once every 4 months during the treatment period. * Nusinersen will be given through a lumbar puncture, which involves injecting the drug into the fluid around the spinal cord in the lower back. * The treatment period will last for up to 64 months (1921 days). * There will be a follow-up safety period that lasts from 4 to 8 weeks. * In total, participants will have up to 19 study visits. Participants will stay in the study for close to 6 years.
Conditions
- Muscular Atrophy, Spinal
Interventions
NusinersenDrug
Administered as specified in the treatment arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to Day 1921
- Change from Baseline in Growth ParametersTime frame: Up to Day 1921
- Number of Participants With Shifts from Baseline in Clinical Laboratory ParametersTime frame: Up to Day 1921
- Number of Participants With Shifts from Baseline in Electrocardiogram (ECG)Time frame: Up to Day 1921
- Number of Participants With Shifts from Baseline in Vital SignsTime frame: Up to Day 1921
- Change from Baseline in Activated Partial Thromboplastin Time (aPTT)Time frame: Up to Day 1921
- Change from Baseline in Prothrombin Time (PT)Time frame: Up to Day 1921
- Change from Baseline in International Normalized Ratio (INR)Time frame: Up to Day 1921
- Change from Baseline in Urine Total ProteinTime frame: Up to Day 1921
- Change from Baseline in Neurological Examination Outcomes for Participants ≤2 Years of AgeTime frame: Up to Day 1921
- Number of Participants with Change from Baseline in Neurological Examination Outcomes for Participants >2 Years of AgeTime frame: Up to Day 1921
- Percentage of Participants With a Postbaseline Platelet Count Below the Lower Limit of Normal on at least 2 Consecutive MeasurementsTime frame: Up to Day 1921
- Percentage of Participants With a Postbaseline Corrected QT Interval Using Fridericia's Formula (QTcF) of >500 millisecond (msec) and an Increase from Baseline to Any Postbaseline Timepoint in QTcF of >60 msecTime frame: Up toDay 1921
Locations
39 sites in 16 countries. Site status is shown where the registry gives one.
Stanford University Medical Center
Sacramento, California
Children's Hospital Colorado
Aurora, Colorado
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
The Johns Hopkins Hospital
Baltimore, Maryland
Boston Children's Hospital
Boston, Massachusetts
St. Jude Children's Research Hospital
Memphis, Tennessee
Children's Medical Center
Plano, Texas
Hospital de Clínicas de Porto Alegre
Porto Alegre, Brazil
Hospital das Clinicas - FMUSP
São Paulo, Brazil
London Health Sciences Centre (LHSC) - Children's Hospital
London, Ontario, Canada
Hospital Luis Calvo Mackenna
Santiago, Chile
Clinica Las Condes
Santiago, Chile
Clinica MEDS La Dehesa
Santiago, Chile
Peking University First Hospital
Beijing, Beijing Municipality, China
Guangzhou Woman and Children's Medical Center
Guangzhou, Guangdong, China
The Children's Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Hospital Universitario San Ignacio
Bogotá, Colombia
Tallinn Children's Hospital
Tallinn, Estonia
Universitaetsklinikum Freiburg
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Universitaetsklinikum Giessen und Marburg GmbH
Giessen, Hesse, Germany
Fondazione Serena Onlus - Centro Clinico Nemo
Milan, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, Italy
Kurume University Hospital
Kurume-shi, Fukuoka, Japan
Hyogo Medical University Hospital
Nishinomiya-shi, Hyōgo, Japan
Tokyo Women's Medical University Hospital
Shinjuku-ku, Tokyo-To, Japan
Saint George University Hospital Medical Center
Beirut, Lebanon
Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde
Guadalajara, Mexico
Instituto Nacional de Pediatria
Mexico City, Mexico City, Mexico
Hospital Infantil de Mexico Federico Gomez
Mexico City, Mexico City, Mexico
Russian Children Neuromuscular Center of Veltischev
Moskva, Russia
Regional Pediatric Clinical Hospital #1
Yekaterinburg, Russia
King Fahad Specialist Hospital
Dammam, Saudi Arabia
National Guard Health Affairs: King Abdulaziz Medical City
Jeddah, Saudi Arabia
King Faisal Specialist Hospital & Research Center
Riyadh, Saudi Arabia
Hospital Universitario La Paz
Madrid, Spain
Hospital Universitari i Politecnic La Fe
Valencia, Spain
Hospital Sant Joan de Deu
Esplugues Del Llobregat, Barcelona, Spain
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.